CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apnimed, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders, today announced the results of a Phase 1 study for a component of the company’s lead combination drug candidate, AD109, which is being explored as a pharmacologic treatment for Obstructive Sleep Apnea (OSA). In this healthy volunteer study, R-oxybutynin, a key component of AD109, demonstrated a favorable pharmacokinetic (PK) profile and was well tolerated with no adverse events related to the study drug.
Dermavant Sciences has lured David Rubenstein, M.D., Ph.D., away from GlaxoSmithKline to serve as its CSO. The Roivant company unveiled the hire alongside other executive appointments and news of the in-licensing of a drug to treat excessive sweating.
Accord`s Generic Oxybutynin Chloride approved in US for Overactive Bladder
Amneal Signs Deal to Acquire the Generic Business of Actavis Australia